ITB-Med AB (Publ) has announced the completion of an equity investment of up to $67 million, led by Mr. Pablo Legorreta, the founder and CEO of Royalty Pharma.

ITB-Med is a biopharmaceutical company focusing on the development of specific immunomodulatory biologics for use primarily in organ and stem cell transplantation.

The funding will allow ITB-Med to continue to optimize its research efforts led by world-class researchers and clinicians to develop groundbreaking treatments for transplant patients.

Carnegie Investment Bank is financial advisor and Baker McKenzie acted as legal advisor to ITB-Med in connection with the equity investment. Baker McKenzie's team consisted mainly of Joakim Falkner, Anna Orlander and Ian Gulam.